EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

Sumanta K Pal iD, Yohann Loriot iD, Andrea Necchi iD, Parminder Singh iD, Daniel Castellano iD, Lance Pagliaro, Cristina Suarez iD, Bradley A McGregor iD, Ulka N Vaishampayan iD, Ralph J Hauke iD, Thomas Powles iD, Carla M L Van Herpen iD und 6 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01675 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Sumanta K Pal und 17 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope Comprehensive Cancer Center, Duarte, CA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Anilides, Antineoplastic Combined Chemotherapy Protocols, Pyridines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC). METHODS This phase Ib study (ClinicalTrials.gov identifier: NCT03170960 ) enrolled patients with inoperable locally advanced/metastatic UC into four tumor cohorts: first-line cisplatin-eligible (cis-eligible), first-line cisplatin-ineligible (cis-ineligible), previous platinum-containing chemotherapy (previous chemotherapy-treated), and previous immune checkpoint inhibitor (ICI)–treated. Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator per RECIST v1.1 every 6 weeks for 12 months and every 12 weeks thereafter; the secondary end point was safety. RESULTS A total of 121 patients (previous ICI-treated cohort, n = 31, and each of the other cohorts, n = 30) received study treatment from March 2018 to November 2021. The ORR (95% CI) was 30% (15 to 49) for cis-eligible, 20% (8 to 39) for cis-ineligible, 27% (12 to 46) for previous chemotherapy-treated, and 10% (2 to 26) for previous ICI-treated cohorts. The median progression-free survival (95% CI) was 5.5 (1.6 to 11.6), 5.6 (3.1 to 11.1), 5.4 (1.6 to 7.6), and 3.0 (1.8 to 5.5) months, respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) were experienced by 43%, 67%, 57%, and 45% of patients, respectively. TRAEs led to discontinuation of all treatment components in 17%, 13%, 3%, and 19%, respectively. No grade 5 TRAEs were reported in any cohort. CONCLUSION The novel combination of cabozantinib plus atezolizumab exhibited clinical activity in advanced UC that is cis-eligible, cis-ineligible, or previously treated with platinum-containing chemotherapy; clinical activity in previous ICI-treated UC was modest. The toxicity profile was consistent with that previously reported for the combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAnilidesAntineoplastic Combined Chemotherapy ProtocolsPyridinesUrologic NeoplasmsCarcinoma, Transitional CellHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultNeoplasm Metastasis

Substanzen

atezolizumabcabozantinibAntibodies, Monoclonal, HumanizedAnilidesPyridines

Autor:innen und Institutionen

  • City of Hope Comprehensive Cancer Center, Duarte, CA.
  • DITEP, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy.
  • Department of Oncology, Mayo Clinic, Phoenix, AZ.
  • Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Oncology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Sumanta K Pal, Yohann Loriot, Andrea Necchi, Parminder Singh, Daniel Castellano, Cristina Suarez, Bradley A McGregor, Ulka N Vaishampayan, Ralph J Hauke, Thomas Powles, Carla M L Van Herpen, Kevin D Courtney, Robert Dreicer, Neeraj Agarwal

Förderung

  • NCI NIH HHS

Zitieren

APA

Pal, S. K., Loriot, Y., Necchi, A., Singh, P., Castellano, D., Pagliaro, L., Suarez, C., McGregor, B. A., Vaishampayan, U. N., Hauke, R. J., Powles, T., Van Herpen, C. M. L., Courtney, K. D., Dreicer, R., Sudhagoni, R., Schwickart, M., Andrianova, S., & Agarwal, N. (2025). COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01675

Vancouver

Pal SK, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, et al. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01675

BibTeX
@article{Pal2025,
  author = {Pal, Sumanta K and Loriot, Yohann and Necchi, Andrea and Singh, Parminder and Castellano, Daniel and Pagliaro, Lance and Suarez, Cristina and McGregor, Bradley A and Vaishampayan, Ulka N and Hauke, Ralph J and Powles, Thomas and Van Herpen, Carla M L and Courtney, Kevin D and Dreicer, Robert and Sudhagoni, Ramu and Schwickart, Martin and Andrianova, Svetlana and Agarwal, Neeraj},
  title = {COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01675}
}
Kostenlos starten →